PRDM16-DT

Across TCGA pan-cancer cohorts, PRDM16-DT RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PRDM16-DT data layer compared with 1 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PRDM16-DT RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRDM16-DT expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUAD show a favorable association.

ACC, SKCM, and UVM are the cancer types where PRDM16-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Quartile	II,III,IV	0.073	0.458	.002	77	view →
SKCM	DFS	Quartile	II,III,IV	0.743	0.386	<.001	72	view →
UVM	DFS	Median	All	0.429	0.731	<.001	60	view →
KIRP	DFS	Tertile	All	0.451	1.000	<.001	54	view →
LUAD	OS	Median	All	0.445	0.243	<.001	51	view →
LAML	DFS	Median	All	0.445	0.690	<.001	44	view →
SARC	OS	Quartile	All	0.895	0.720	.001	31	view →
DLBC	DFS	Tertile	All	1.000	0.606	.003	29	view →
READ	OS	Tertile	II,III,IV	0.486	0.790	.004	21	view →
UCS	DFS	Quartile	II,III,IV	0.546	0.230	.024	14	view →
KIRC	DFS	Quartile	All	0.710	0.481	.013	11	view →
LUSC	DFS	Median	IV	0.134	0.827	.014	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PRDM16-DT–ACC (DFS)

Open the ACC breakdown →